Drug intelligence / Profile preview

acetylsalicylic acid + escitalopram

Development stage
Unknown
Lead developer
Lundbeck
Modality
Small Molecules
Administration
Oral
01

Overview

Acetylsalicylic acid + escitalopram is a combination of two pharmaceutical agents. Acetylsalicylic acid (commonly known as aspirin) is a nonsteroidal anti-inflammatory drug (NSAID) that acts primarily as an irreversible inhibitor of cyclooxygenase enzymes, leading to reduced synthesis of prostaglandins and thromboxanes, which results in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) used mainly for the treatment of major depressive disorder and generalized anxiety disorder; it works by increasing synaptic serotonin levels through inhibition of the serotonin transporter. The combination does not have a unique brand or code name and is not marketed as a fixed-dose product but may be co-prescribed in clinical practice. Coadministration increases the risk of bleeding due to additive effects on platelet function[1][2][5][8].

Other names
aspirin + escitalopram
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)SERT (Sodium-dependent serotonin transporter)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on acetylsalicylic acid + escitalopram.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on acetylsalicylic acid + escitalopram.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call